Global Clinical Oncology Next Generation Sequencing Market Top Major Players 2024, Forecast To 2033
9 Jan, 2024
The clinical oncology next-generation sequencing market has experienced rapid growth, surging from $0.45 billion in 2023 to $0.52 billion in 2024, showcasing a notable 15.5% CAGR. Historical growth factors involve advancements in genomic research, cancer biomarker discoveries, technological progress, and regulatory approvals. The market is poised for continued rapid expansion, with expectations to reach $0.86 billion in 2028, reflecting a CAGR of 13.2%. Anticipated influencers include rising cancer incidence rates, the growth of precision medicine, the prominence of immuno-oncology, and the adoption of liquid biopsies.
Global Clinical Oncology Next Generation Sequencing Market Key Driver
The clinical oncology next-generation sequencing market is expected to witness growth, propelled by the escalating global cancer cases. In 2021, the USA reported 1.9 million new cases and 0.6 million cancer deaths. The four most prevalent cancer types, contributing to 43% of new cases globally, include lung, prostate, bowel, and female breast cancer. The rising global cancer incidence is foreseen to drive demand, fostering growth in the clinical oncology next-generation sequencing market.
Get A Free Sample Of The Global Clinical Oncology Next Generation Sequencing Market ReportGlobal Clinical Oncology Next Generation Sequencing Market Segments
The clinical oncology next generation sequencing market covered in this report is segmented –
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories
By Geography: The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Clinical Oncology Next Generation Sequencing Industry Players
Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
Get The Full Global Clinical Oncology Next Generation Sequencing Market Report
Clinical Oncology Next Generation Sequencing Market Overview
Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy.
Clinical Oncology Next Generation Sequencing Global Market Report 2023 provides data on the global clinical oncology next generation sequencing market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The clinical oncology next generation sequencing market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.